Lineage Cell Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Lineage Cell Therapeutics, Inc. (NYSE American: LCTX) is a clinical-stage biotechnology company pioneering the development of novel, allogeneic ("off-the-shelf") cell therapies designed to address serious medical conditions with significant unmet needs. The company's pipeline is built on its proprietary, in-house cell-based manufacturing platform, AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering). By applying directed differentiation protocols to pluripotent stem cell lines, Lineage designs and manufactures specialized human cells that mimic or replace dysfunctional cells naturally found in the body. Key clinical programs include OpRegen, a retinal pigment epithelial cell therapy in Phase 2a development in collaboration with Roche and Genentech for geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for spinal cord injuries; and ReSonance (ANP1), an auditory neuronal progenitor cell therapy in development with William Demant Invest A/S.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Development and scaling of the proprietary AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering) platform. This includes the AlloSCOPE '5D' application aimed at higher scale production of specialized human cells with reduced manipulation.
Expected impact: Enables large-scale, cost-effective, and consistent production of off-the-shelf cell therapies, enhancing the commercial viability of the entire pipeline.
A cell therapy manufacturing initiative focused on the large-scale production of undifferentiated pluripotent cells. If successful, the technology could be evaluated for the production of islet cells to support a potential treatment for Type 1 Diabetes.
Expected impact: Expands the company's therapeutic reach into endocrine disorders and provides a new high-value candidate for potential strategic partnerships.
Preclinical development of COR1, a corneal endothelial disease cell therapy program launched in early 2026 to address vision loss due to corneal dysfunction.
Expected impact: Broadens the ophthalmic pipeline beyond retinal diseases, leveraging the company's cell transplant expertise.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Jointly advances the preclinical development of Lineage's auditory neuronal cell transplant program, ReSonance (ANP1), for the treatment of hearing loss and auditory neuropathy.
Terms: WDI will contribute up to $12 million in research collaboration costs over a three-year term.
Exclusive worldwide rights granted to Roche/Genentech to develop and commercialize OpRegen (RG6501) for the treatment of ocular disorders, including geographic atrophy secondary to dry AMD.
Terms: Lineage received a $50 million upfront payment and is eligible to receive up to $620 million in additional developmental, regulatory, and commercialization milestone payments, plus tiered double-digit royalties on net sales.